Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study

To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS).A randomized, placebo-controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive MS. In this secondary analysis of a previously reported trial, secondary and tertiary endpoints included gray matter atrophy, new or enlarging T2 lesions as measured every 24...